TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06176690

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing C7R.CD30.CAR-EBVST cells for people whose ALK-negative ALCL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

Who can join (key eligibility)

  • Age 12 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

C7R.CD30.CAR-EBVST cells (BIOLOGICAL): The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.

Drugs / treatments
C7R.CD30.CAR-EBVST cells
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

NCT06176690

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing C7R.CD30.CAR-EBVST cells for people whose ALK-negative ALCL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 2 US locations.

Who can join

  • Age 12 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment

What's being tested

C7R.CD30.CAR-EBVST cells (BIOLOGICAL): The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.

Drugs / treatments: C7R.CD30.CAR-EBVST cells

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 90 patients

Primary endpoint: Dose Limiting Toxicity (DLT)

Ages: 12 Years to 75 Years

Start date: 2025-10-27 | Est. completion: 2043-06-27

Locations

2 US sites · 2 total

Texas

Contact

Premal Lulla, MD | lulla@bcm.edu | 713-441-1450

Sponsor: Baylor College of Medicine (OTHER)

Tags

ALCL ALK− · ALCL ALK+ · ENKTL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06176690

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.